Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
143 hedge funds and large institutions have $1.53B invested in Apellis Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 63 increasing their positions, 34 reducing their positions, and 23 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 34
52% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 23
14% more capital invested
Capital invested by funds: $1.34B → $1.53B (+$188M)
8% more funds holding
Funds holding: 133 → 143 (+10)
7.17% more ownership
Funds ownership: 68.69% → 75.86% (+7.2%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
53% less call options, than puts
Call options by funds: $5.34M | Put options by funds: $11.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$215M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$55.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$53.3M |
| 4 |
BlackRock
New York
|
+$37.6M |
| 5 |
Jennison Associates
New York
|
+$35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$34.5M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$24.5M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$18M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
-$17.7M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.4M |
APLS Hedge Fund Activity: Q1 2020 in Review
143 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2020, worth a combined $1.53B — up 14% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new APLS positions and 23 closed out — a net gain of 12 holders — while 63 added to existing stakes and 34 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $215M. The largest seller was Barclays, cutting an estimated $34.5M.
- 143 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2020, up from 133 in Q4 2019.
- Funds reported $1.53B of Apellis Pharmaceuticals stock for Q1 2020, up 14% quarter-over-quarter.
- 35 funds opened new Apellis Pharmaceuticals positions in Q1 2020 and 23 closed out, a net change of +12 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2020 was Wellington Management Group, an estimated $215M added.
- The largest Apellis Pharmaceuticals seller in Q1 2020 was Barclays, an estimated $34.5M sold.
Based on aggregated 13F filings for Q1 2020.